IgAN Insights from Treatment Experience (IgNITE): A Multicountry Integrated Framework to Advance Real-World Evidence in IgAN (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #INFO11-SA; Pres time: Oct 24, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "IgNITE is a global umbrella RWE program designed to evaluate IgAN patients receiving novel therapies, including iptacopan and atrasentan, focusing on baseline characteristics, treatment patterns and long-term outcomes. The program accommodates differences in data maturity, treatment availability, local regulations, governance requirements and operational readiness. IgNITE aspires to advance understanding of IgAN, its progression and treatments in the real world, for patients and the wider healthcare community."
Clinical • HEOR • Real-world • Real-world evidence • Glomerulonephritis • IgA Nephropathy • Nephrology • Renal Disease
|
|
Dana V. Rizk; Jun Wada; Sydney Tang; Daniel Gallego; Ceri Hirst; Manasi Mital Desai; Dimitra Koukaroudi; Tobias B. Huber
|